「ex」の検索結果
128件：31～35件目を表示
-
Product Development Policy | Research & Development | SENJU Pharmaceutica
Product Strategy DivisionExecutive OfficerYasunobu Maenaka With the management philosophy of “Good Company” and a company that shapes “Beyond eyesight,” Senju Pharmaceutical has developed products tha...
http://www.senju.co.jp/english/rd/policy/ -
R&D Pipeline | Research & Development | SENJU Pharmaceutica
PROGRESS OF DEVELOPMENT Disclosuring of information after Phase 1 DrugIndicationStatus (Region) SJP-0132Dry eyeLaunched（Japan） PranoprofeninflammationApplication under review (Vietnam) SJP-0132Dry eye
http://www.senju.co.jp/english/rd/pipeline.html -
Publications | Research & Development | SENJU Pharmaceutica
lugfelder2 1: Senju Pharmaceutical Co., Ltd, Hyogo, Japan. 2: Baylor College of Medicine, Houston, Texas, USA American Journal of Ophthalmology. 2026:284:216-225. VIEW PUBLICATION Comprehensive genot...
http://www.senju.co.jp/english/rd/thesis/ -
NewMytear CL Ice Refresh | OTC Products, etc. | Products | SENJU Pharmaceutical
et with you. If there is no improvement in your blurred vision. If you wear hard contact lenses and experience increased amount of discharge such as eye mucus and the lenses become clouded. If there i...
http://www.senju.co.jp/english/products/mytearir.html -
タフルプロスト点眼液0.0015%「センジュ」
, 2010；114：436-443 8） タプロス点眼液0.0015％：第Ⅲ相比較試験 （承認年月日：2008 年10月16日、申請資料概要2.7.6.4） 9） Takagi Y, et al.：Exp Eye Res, 2004；78, 767-776 10） タプロス点眼液0.0015％：受容体親和性及び選択性に関する検 討 （承認年月日：2008年10月16日、申請資料概要2.6.2.2...
https://www.senju.co.jp/system/files/product_other_file/2024-12/tafluprost_202402_C3.pdf